A Phase 3 interventional study of empagliflozin 10 mg + linagliptin 5 mg and empagliflozin 10 mg in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 83 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-09-06.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.
Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 15th largest by enrollment, is one of 5 that started in 2015, is one of 28 in phase 3, and was the 33rd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–75
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
Celltrion · Sites in Korea, Republic of
Ages 19+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 30–75
By country, each count listing its studies:
empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 5 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 880 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 79 across the 130 interventional studies. Of the 91 that completed or were terminated, 38 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 130 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim: 2 open now, 3 under way, 2 of them phase 3. Of 125 finished, 109 (87%) have results posted.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 18th largest by enrollment of the 96 interventional ones that give a count, is one of 7 that started in 2015, is one of 50 in phase 3, and was the 95th registered.
Boehringer Ingelheim’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
10 of the studies testing empagliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07093476Phase 3CelltrionEfficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin | 2026-12 |
| NCT05164263Getz PharmaReal World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study | 2026-12-31 |
| NCT06989723Seoul National University Bundang HospitalPioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes | 2026-12-31 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT05960656The University of Texas Health Science Center at San AntonioSGLTi, Hepatic Glucose Production and Ketogenesis | 2027-06-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Among Boehringer Ingelheim’s 130 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
Two independent study parts (i.e. Part A and Part B) are included in this trial. Part A will evaluate empagliflozin 10 mg + linagliptin and Part B will evaluate empagliflozin 25 mg + linagliptin. All analyses will be carried out separately for these study parts. The objective of Part A is to investigate the efficacy, safety and tolerability of the fixed dose combination (FDC) of empagliflozin 10 mg / linagliptin 5 mg compared with empagliflozin 10 mg plus FDC matching placebo administered orally once daily for 24 weeks in Japanese patients with T2DM (Type 2 Diabetes Mellitus) who have insufficient glycaemic control after 16 weeks of treatment with empagliflozin 10 mg alone once daily. The study is designed to show superiority of the FDC of empagliflozin 10 mg / linagliptin 5 mg over empagliflozin 10 mg plus FDC matching placebo after 24 weeks of treatment. The objective of Part B is to investigate the efficacy, safety and tolerability of the FDC of empagliflozin 25 mg / linagliptin 5 mg compared with empagliflozin 25 mg plus FDC matching placebo administered orally once daily for 24 weeks in Japanese patients with T2DM who have insufficient glycaemic control after 16 weeks of treatment with empagliflozin 25 mg alone once daily. The study is designed to show superiority of the FDC of empagliflozin 25 mg / linagliptin 5 mg over empagliflozin 25 mg plus FDC matching placebo after 24 weeks of treatment. The 24 week treatment period will be followed by a 28 week extension treatment period to evaluate further efficacy and safety up to 52 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male and female patients on diet and exercise regimen for at least 12 weeks prior to informed consent who are:
(HbA1c) at Visit 1 (screening)
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patient to receive a tablet containing low dose empagliflozin and linagliptin once daily
Drug: empagliflozin 10 mg + linagliptin 5 mg
patient to receive a tablet containing low dose empagliflozin once daily
Drug: empagliflozin 10 mg · Drug: Placebo
patient to receive a tablet containing high dose empagliflozin and linagliptin once daily
Drug: empagliflozin 25 mg + linagliptin 5 mg
patients to receive a tablet containing high dose empagliflozin once daily
Drug: empagliflozin 25 mg · Drug: Placebo
Drug page: Empagliflozin
empagliflozin low dose + linagliptin once daily
empagliflozin low dose once daily
Drug page: Empagliflozin
empagliflozin high dose + linagliptin once daily
empagliflozin high dose once daily
Change in Glycated Haemoglobin A1c (HbA1c) (%) From Baseline After 24 Weeks of Treatment
Change from baseline in HbA1c (%) after 24 weeks of treatment with double-blind trial medication. Change was calculated as: HbA1c value at 24-week - HbA1c value at baseline, for each patient. Baseline was defined as the last observation before the first intake of double-blind randomised trial medication. Statistical analysis presented is based on a restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) approach. Full Analysis Set (Observed Cases) \[FAS (OC)\]: This analysis set consisted of all patients who were randomised and treated with at least 1 dose of trial drug during the double-blind part of the trial and who had a baseline HbA1c assessment and at least 1 on-treatment HbA1c assessment during the 24-week double-blind part of the trial. Observed cases analysis included only the available data that were observed while patients were on treatment, i.e., excluding the missing data.
Time frame: Baseline and 24 week
| Milestone | Empagliflozin 10 mg OL | Empagliflozin 25 mg OL | Empagliflozin 10 mg + Linagliptin 5 mg | Empagliflozin 10 mg + Placebo | Empagliflozin 25 mg + Linagliptin 5 mg | Empagliflozin 25 mg + Placebo |
|---|---|---|---|---|---|---|
| Started | 439 | 440 | 0 | 0 | 0 | 0 |
| Completed | 215 | 232 | 0 | 0 | 0 | 0 |
| Not completed | 224 | 208 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 14 | 7 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 7 | 0 | 0 | 0 | 0 |
| Withdrew: Other than specified above | 204 | 189 | 0 | 0 | 0 | 0 |
| Milestone | Empagliflozin 10 mg OL | Empagliflozin 25 mg OL | Empagliflozin 10 mg + Linagliptin 5 mg | Empagliflozin 10 mg + Placebo | Empagliflozin 25 mg + Linagliptin 5 mg | Empagliflozin 25 mg + Placebo |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 107 | 108 | 116 | 116 |
| Completed | 0 | 0 | 105 | 100 | 110 | 108 |
| Not completed | 0 | 0 | 2 | 8 | 6 | 8 |
| Withdrew: Adverse event | 0 | 0 | 2 | 6 | 4 | 5 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 | 0 | 2 |
| Withdrew: Other than specified above | 0 | 0 | 0 | 0 | 1 | 0 |
Change from baseline in HbA1c (%) after 24 weeks of treatment with double-blind trial medication. Change was calculated as: HbA1c value at 24-week - HbA1c value at baseline, for each patient. Baseline was defined as the last observation before the first intake of double-blind randomised trial medication. Statistical analysis presented is based on a restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) approach. Full Analysis Set (Observed Cases) \[FAS (OC)\]: This analysis set consisted of all patients who were randomised and treated with at least 1 dose of trial drug during the double-blind part of the trial and who had a baseline HbA1c assessment and at least 1 on-treatment HbA1c assessment during the 24-week double-blind part of the trial. Observed cases analysis included only the available data that were observed while patients were on treatment, i.e., excluding the missing data.
| Percentage (%) | Empagliflozin 10 mg + Linagliptin 5 mg | Empagliflozin 10 mg + Placebo | Empagliflozin 25 mg + Linagliptin 5 mg | Empagliflozin 25 mg + Placebo |
|---|---|---|---|---|
| Change in Glycated Haemoglobin A1c (HbA1c) (%) From Baseline After 24 Weeks of Treatment | -0.94 ± 0.05 | -0.12 ± 0.06 | -0.91 ± 0.05 | -0.33 ± 0.05 |
Collected over From first drug administration till two weeks after last drug administration; up to 72 weeks (including 16 weeks open-label, 2 weeks run-in period and 52 weeks double-blind treatment period).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Empagliflozin 25 mg + Linagliptin 5 mg | — | 6/116 (5.2%) | 54/116 (46.6%) |
| Empagliflozin 10 mg + Linagliptin 5 mg | — | 1/107 (0.9%) | 24/107 (22.4%) |
| Empagliflozin 25 mg + Placebo | — | 8/116 (6.9%) | 51/116 (44%) |
| Empagliflozin 10 mg + Placebo | — | 4/108 (3.7%) | 36/108 (33.3%) |
| Empagliflozin 25 mg OL | — | 11/440 (2.5%) | 131/440 (29.8%) |
| Empagliflozin 10 mg OL | — | 9/439 (2.1%) | 120/439 (27.3%) |
| Event | Empagliflozin 25 mg + Linagliptin 5 mg | Empagliflozin 10 mg + Linagliptin 5 mg | Empagliflozin 25 mg + Placebo | Empagliflozin 10 mg + Placebo | Empagliflozin 25 mg OL | Empagliflozin 10 mg OL |
|---|---|---|---|---|---|---|
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/116 | 1/107 | 1/116 | 0/108 | 0/440 | 0/439 |
| SepsisInfections and infestations | 0/116 | 0/107 | 0/116 | 1/108 | 0/440 | 0/439 |
| Disseminated intravascular coagulationBlood and lymphatic system disorders | 0/116 | 0/107 | 0/116 | 1/108 | 0/440 | 0/439 |
| Acute myocardial infarctionCardiac disorders | 0/116 | 0/107 | 0/116 | 1/108 | 0/440 | 0/439 |
| Atrial flutterCardiac disorders | 0/116 | 0/107 | 0/116 | 1/108 | 0/440 | 0/439 |
| CholangitisHepatobiliary disorders | 0/116 | 0/107 | 0/116 | 1/108 | 0/440 | 0/439 |
| Femur fractureInjury, poisoning and procedural complications | 0/116 | 0/107 | 0/116 | 1/108 | 0/440 | 0/439 |
| Metastases to boneNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/116 | 0/107 | 1/116 | 0/108 | 0/440 | 0/439 |
| Metastases to lymph nodesNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/116 | 0/107 | 1/116 | 0/108 | 0/440 | 0/439 |
| Anaphylactic shockImmune system disorders | 1/116 | 0/107 | 0/116 | 0/108 | 0/440 | 0/439 |
| Event | Empagliflozin 25 mg + Linagliptin 5 mg | Empagliflozin 10 mg + Linagliptin 5 mg | Empagliflozin 25 mg + Placebo | Empagliflozin 10 mg + Placebo | Empagliflozin 25 mg OL | Empagliflozin 10 mg OL |
|---|---|---|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 31/116 | 16/107 | 34/116 | 24/108 | 46/440 | 47/439 |
| Blood ketone body increasedInvestigations | 16/116 | 2/107 | 9/116 | 11/108 | 40/440 | 26/439 |
| PollakiuriaRenal and urinary disorders | 0/116 | 0/107 | 0/116 | 1/108 | 35/440 | 30/439 |
| Weight decreasedInvestigations | 2/116 | 0/107 | 7/116 | 1/108 | 10/440 | 16/439 |
| Back painMusculoskeletal and connective tissue disorders | 7/116 | 3/107 | 2/116 | 3/108 | 5/440 | 2/439 |
| PeriodontitisInfections and infestations | 3/116 | 0/107 | 6/116 | 1/108 | 2/440 | 2/439 |
| ConstipationGastrointestinal disorders | 5/116 | 2/107 | 6/116 | 0/108 | 11/440 | 10/439 |
| ContusionInjury, poisoning and procedural complications | 4/116 | 3/107 | 6/116 | 1/108 | 3/440 | 4/439 |
Open-label full analysis set (OLFAS) consisted of all patients in the open-label period who received at least 1 dose of open-label study drug during the trial and had a pre-treatment Glycated haemoglobin A1c (HbA1c) assessment and at least 1 on-treatment HbA1c assessment during the open-label part of the trial.
| Age, Continuous(Years) | Empagliflozin 10 mg OL | Empagliflozin 25 mg OL | Total |
|---|---|---|---|
| Mean | 56.8 ± 10.2 | 57.5 ± 10.0 | 57.2 ± 10.1 |
| Sex: Female, Male(Participants) | Empagliflozin 10 mg OL | Empagliflozin 25 mg OL | Total |
|---|---|---|---|
| Female | 111 | 124 | 235 |
| Male | 324 | 309 | 633 |
Ran from May 2015 to primary completion in Nov 2016, 18 months.
Results were first posted in Sep 2018, 1 year 9 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 18 months is close to that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Empagliflozin